362 related articles for article (PubMed ID: 32548981)
1. Neovascular glaucoma in patients with central retinal vein occlusion: A real-life study in the anti-VEGF era.
Casselholm de Salles M; Lindberg C; Epstein D
Acta Ophthalmol; 2021 Feb; 99(1):e7-e12. PubMed ID: 32548981
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors.
Light JG; Tian J; Wenick AS
Ophthalmol Retina; 2021 Sep; 5(9):888-900. PubMed ID: 33227561
[TBL] [Abstract][Full Text] [Related]
3. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.
Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
6. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
Theodoropoulou S; Ellabban AA; Johnston RL; Cilliers H; Mohamed Q; Sallam AB
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):725-732. PubMed ID: 27878430
[TBL] [Abstract][Full Text] [Related]
7. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
[TBL] [Abstract][Full Text] [Related]
8. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
Hu Q; Li H; Xu W; Du Y; Ma C; He J
Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
[No Abstract] [Full Text] [Related]
10. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison.
Gado AS; Macky TA
Clin Exp Ophthalmol; 2014; 42(7):650-5. PubMed ID: 24612095
[TBL] [Abstract][Full Text] [Related]
14. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA; Scott IU; VanVeldhuisen PC; King J; Ip MS; Blodi BA; Oden NL;
JAMA Ophthalmol; 2021 Dec; 139(12):1285-1291. PubMed ID: 34709363
[TBL] [Abstract][Full Text] [Related]
15. Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: A retrospective study.
Sweta VD; Shibi Dev BN; Sandhya R
Indian J Ophthalmol; 2022 Feb; 70(2):585-589. PubMed ID: 35086242
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.
Sun Y; Liang Y; Zhou P; Wu H; Hou X; Ren Z; Li X; Zhao M
BMC Ophthalmol; 2016 Aug; 16(1):150. PubMed ID: 27576739
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
18. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
[TBL] [Abstract][Full Text] [Related]
19. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein Occlusion-Related Macular Edema with Systemic Hypertension.
Kida T; Osuka S; Fukumoto M; Sato T; Harino S; Oku H; Ikeda T
Ophthalmologica; 2020; 243(2):102-109. PubMed ID: 31851998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
